Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vanda And Nektar Persevere With Fanapt And Onzeald In EU

Executive Summary

The two products that the European Medicines Agency’s key scientific committee, the CHMP, decided last week should not be approved in the EU were Vanda’s schizophrenia treatment Fanaptum (iloperidone), and Onzeald (etirinotecan pegol), a potentially new treatment for breast cancer with brain metastases from Nektar/Daiichi Sankyo Europe. The companies want the CHMP to look again at the negative opinions they received.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts